Should autistic children be treated with marijuana?

Should autistic children be treated with marijuana?

Some groups of parents and pro-marijuana advocates are calling for cannabis to be considered as a treatment for children and young people with a range of developmental conditions and behavioural issues.

A review paper in the Journal of Developmental & Behavioural Paediatrics, authored by experts from Boston Children’s Hospital, highlighted concerns about a number of groups advocating the use of medical marijuana for children with autism, ADHD and other conditions, citing animal research and a small number of clinical reports that claim benefits.

The researchers note that any benefits that have been seen are likely from cannabidiols – currently being looked at for the treatment of rare forms of epilepsy – rather than tetrahydrocannabinol (THC), the psychoactive constituent of cannabis.

This taken together with a growing willingness to prescribe cannabis could lead to the issuing of medical marijuana for developmental or behavioural problems, for which there is insufficient evidence as of yet.

Scott Hadland, John R. Knight and Sion Kim Harris, said this is concerning: “Given the current scarcity of data, cannabis cannot be safely recommended for the treatment of developmental or behavioural disorders at this time.”

The authors also say that the lack of research means using medical marijuana for these purposes could result in long-term damage, with the drug harming the developing brain.

“Children with severe ASD cannot communicate verbally and may relate to the world through loud, repetitive shrieking and hand-flapping that is very disruptive to their families and all those around them,” Knight said.

“So my heart goes out to families who are searching for something, anything to help their child. But in using medicinal marijuana they may be trading away their child’s future for short-term symptom control.”

While medical marijuana has been shown to be beneficial for some conditions, such as pain relief, there is also growing evidence to show long-term and possibly irreversible damage to mental and physical health.

Leonard Rappaport, from the Division of Developmental Medicine at Boston Children’s Hospital, commented on the paper: “The scant research that we have on adolescent use is alarming enough. But we are really moving into entirely new territory when we consider giving cannabis to children as that has not even been done in neuro-typical children, let alone those with developmental or behavioural problems.”

The authors concluded: “At this time, good evidence is almost entirely lacking for its application in paediatric developmental and behavioural conditions.”

Source: Should autistic children be treated with marijuana?


New Study Finds Cannabis To Be Effective In Treating Depression

New Study Finds Cannabis To Be Effective In Treating Depression

Research has suggested that cannabis may be a promising treatment option for a number of different physical and mental health conditions, from post-traumatic stress disorder to chronic pain. A study released this week suggests that depression can be added to that list.

Neuroscientists from the University of Buffalo’s Research Institute on Addictions found that endocannabinoids — chemical compounds in the brain that activate the same receptors as THC, an active compound in marijuana — may be helpful in treating depression that results from chronic stress.

In studies on rats, the researchers found that chronic stress reduced the production of endocannabinoids, which affect our cognition, emotion and behavior, and have been linked to reduced feelings of pain and anxiety, increases in appetite and overall feelings of well-being. The body naturally produces these compounds, which are similar to the chemicals in cannabis. Reduction of endocannabinoid production may be one reason that chronic stress is a major risk factor in the development of depression.

Then, the research team administered marijuana cannabinoids to the rats, finding it to be an effective way to restore endocannabinoid levels in their brains — possibly, thereby, alleviating some symptoms of depression.

“Using compounds derived from cannabis — marijuana — to restore normal endocannabinoid function could potentially help stabilize moods and ease depression,” lead researcher Dr. Samir Haj-Dahmane said in a university press release.

Recent research around marijuana’s effect on symptoms of post-traumatic stress disorder further bolsters the Buffalo neuroscientists’ findings, since both disorders involve the way the brain responds to stress. A study published last year in the journal Neuropsychopharmacology, for instance, found synthetic cannabinoids triggered changes in brain centres associated with traumatic memories in rats, preventing some of the behavioural and physiological symptoms of PTSD. Another study published last year found that patients who smoked cannabis experienced a 75 percent reduction in PTSD symptoms.

However, it’s important to note that the relationship between marijuana and depression is complex. Some research has suggested that regular and heavy marijuana smokers are at a higher risk for depression, although a causal link between cannabis use and depression has not been established. More studies are needed in order to determine whether, and how, marijuana might be used in a clinical context for patients with depression.

Source: New Study Finds Cannabis To Be Effective In Treating Depression


Cannabis Has Been Studied More Than Many FDA Approved Pharmaceuticals

Cannabis Has Been Studied More Than Many FDA Approved Pharmaceuticals

Opponents of legalizing cannabis for medicinal purposes are fond of arguing that the plant must be subjected to the same standards of clinical study and FDA review as conventional medicines. What they fail to mention is that cannabis and its active components have already been subjected to a greater degree of scientific scrutiny than many FDA-approved pharmaceuticals.

According to a just-published analysis of some 200 newly FDA-approved medications, few conventional drugs are tested in multiple, large-scale clinical assessing safety and efficacy trials prior to market approval. “[A]bout a third won approval on the basis of a single clinical trial, and many other trials involved small groups of patients and shorter durations,” reports The Washington Post in its summary of the study, which appears in the January edition of The Journal of the American Medical Association. “Only about 40 percent of approvals included trials in which the new drug was compared with existing drugs on the market.”

By comparison, there exists over 20,000 published studies or reviews in the scientific literature referencing the cannabis plant and its cannabinoids, nearly half of which were published within the last five years, according to a keyword search on PubMed Central, the government repository for peer-reviewed scientific research. Of these, more than 100 are controlled clinical trials assessing the therapeutic efficacy of cannabinoids for a variety of indications.

A 2006 review of 72 of these trials, conducted between the years 1975 and 2004, identifies ten distinct pathologies for which controlled studies on cannabinoids have been published. The review concludes that these trial data “affirm that cannabinoids exhibit an interesting therapeutic potential as antiemetics, appetite stimulants in debilitating diseases (cancer and AIDS), analgesics, as well as in the treatment of multiple sclerosis, spinal cord injuries, Tourette syndrome, epilepsy and glaucoma.”

A 2010 review of 37 additional controlled trials, conducted between the years 2005 and 2009, similarly acknowledges the plant’s efficacy, finding, “Based on the clinical results, cannabinoids present an interesting therapeutic potential mainly as analgesics in chronic neuropathic pain, appetite stimulants in debilitating diseases (cancer and AIDS), as well as in the treatment of multiple sclerosis.” The review estimates that some 6,100 patients suffering from a wide range of ailments have taken part in clinical cannabis trials over the past decades – a far greater cohort of subjects than would typically participate in clinical trials for more conventional therapeutics.

Most recently, a 2012 review of more recent clinical trials conducted by the California Center for Medicinal Research, involving several hundred patients, concluded emphatically: “Recent clinical trials with smoked and vaporized marijuana, as well as other botanical extracts, indicate the likelihood that the cannabinoids can be useful in the management of neuropathic pain, spasticity due to multiple sclerosis, and possibly other indications…Based on evidence currently available the Schedule I classification is not tenable; it is not accurate that cannabis has no medical value, or that information on safety is lacking.”

The bottom line: Scientists now know more about cannabis as a medicine than regulators know about many of the FDA-approved pharmaceuticals that the plant could replace.

Source: Cannabis Has Been Studied More Than Many FDA Approved Pharmaceuticals


Moderate lifetime marijuana smoking associated with airway irritation but not lung function

Moderate lifetime marijuana smoking associated with airway irritation but not lung function

A research study based on analysis of publicly available data has found that recent marijuana use was associated with symptoms of airway inflammation, but that moderate lifetime use was not associated with clinically significant changes in measures of lung function. The study is the largest cross-sectional analysis of the relationship between marijuana use and measures of lung health to date.

Researchers at Emory University analyzed data from the 2007-2010 National Health and Nutrition Examination Survey (NHANES) — an ongoing nationally representative survey conducted through the National Center for Health Statistics. The data included survey questions and standardized spirometry, a screening tool physicians use to look for pulmonary disease.

The NHANES conducts high quality, standardized spirometry to measure lung function through recording the volume of air a person can force out of his or her lungs (forced vital capacity, or FVC) and the volume of air forced out in the first second of the maneuver (forced expiratory volume, or FEV1).

The research results are published online in the Annals of the American Thoracic Society, and will be published in an upcoming print edition.

In the more than 5,000 adult survey participants with data regarding recent marijuana usage and symptoms, 59.1 percent reported having used marijuana at least once in their lifetime, and 12.2 percent reported using marijuana in the prior month.

Increasing frequency of marijuana usage over the prior month was associated with increases in self-reported respiratory symptoms of bronchitis (coughing, wheezing, etc.) but not with clinically significant changes in measures of lung function as measured by spirometry.

In the nearly 3,000 adult participants with data regarding patterns of lifetime marijuana use, cumulative exposure of less than 20 joint-years (one joint year = smoking an average of one joint per day for a year) was not associated with deleterious changes in lung function, as measured by the FVC and FEV1.

Greater than 20 joint-years of exposure, however, was associated with measurable and clinically significant changes in lung function, but the changes displayed a different pattern than those observed in obstructive lung disease from tobacco use and are of uncertain clinical significance to overall lung health, according to the researchers.

“While over 20 joint-years is significantly associated with a change in lung function, it is inconclusive whether or not this represents early lung function impairment similar to long-term tobacco use,” says lead author Jordan A. Kempker, MD, MSc, clinical research fellow in the Division of Pulmonary and Critical Care Medicine in Emory University School of Medicine.

These results may also be due to a relatively low amount of smoke exposure in marijuana smokers compared to tobacco smokers, Kempker explains. Tobacco smokers generally are at risk of pulmonary disease after 20 pack-years of exposure (one pack-year = smoking an average of one pack of cigarettes a day for a year), which represents significantly more smoke exposure than 20 marijuana joint-years.

“Furthermore, smoking marijuana seems to increase symptoms of respiratory irritation, such as bronchitis, and our study was inconclusive about whether those effects are permanent. We also did not study the association of marijuana smoking with the development of cancer,” says Kempker.

Other authors were Eric G. Honig, MD, and Greg S. Martin, MD, MSc, both professors in Emory’s Division of Pulmonary and Critical Care Medicine.

The authors conclude: “With current marijuana smokers reporting a mean joint-year exposure of 15.8 joint-years, these data represent important public health implications. With the shifting political climate in the U.S. these are important public health concerns that necessitate further inquiry into this growing field. Future research directions may potentially target study populations in those states in the U.S. where marijuana is now legally consumed and it will now be more feasible to longitudinally follow users’ consumption patterns, pulmonary function and symptoms.

Source: Moderate lifetime marijuana smoking associated with airway irritation but not lung function


Florida Republican Aims To Legalize Medical Marijuana

Florida Republican Aims To Legalize Medical Marijuana

A top Florida Republican filed a bill Monday that would legalize medical marijuana in the state, just months after a similar ballot measure received a majority of voter support, but fell just short of the percentage needed to pass.

Florida state Sen. Jeff Brandes (R) filed The Florida Medical Marijuana Act, a bill that would allow licensed Florida physicians to prescribe medical marijuana to qualified patients in what would be a far-reaching expansion from the more limited “Charlotte’s Web” medical marijuana law that Gov. Rick Scott (R) signed last year.

The bill lists nine specific diseases for which patients could qualify for prescribed medical marijuana, including cancer, HIV, AIDS, epilepsy, ALS disease (commonly referred to as Lou Gehrig’s disease), multiple sclerosis and any medical condition that causes chronic wasting syndrome, pain or severe nausea.

Medical marijuana appears to be very popular among state voters. A survey from 2014 found that almost 90 percent of voters supported the legal use of medical marijuana, if prescribed by a doctor. In November, a majority of voters, about 58 percent, supported Amendment 2, but state law requires a supermajority of support — 60 percent or higher — so the ballot initiative failed to pass.

Brandes’ legislative assistant, Chris Spencer, told The Huffington Post that this bill isn’t a response to the support for Amendment 2.

“This legislation is about providing another tool for physicians to employ when treating their patients suffering from specific conditions or symptoms,” Spencer said, adding that this is just a continuation of Brandes’ support of the issue, having been on the forefront of last year’s legalization of the high-CBD/low-THC strain of cannabis for medical use in the state. Unlike THC, the main psychoactive compound in marijuana associated with the “high” sensation, CBD is a non-psychoactive ingredient that has shown to be beneficial in some severe cases of epilepsy.

“This is the opening statement in the legislative conversation on this issue, and we look forward to robust dialogue with the members of the House and Senate,” Spencer said.

It’s not clear if the governor would support a robust legal medical marijuana program in the state. Last year, Scott said he was going to vote against Amendment 2, but did sign the “Charlotte’s Web” legislation into law.

But if the statehouse can’t pass the bill, a ballot measure seeking the legalization of medical cannabis is very likely to be put in front of state voters again in 2016.

Robert Capecchi, deputy director of state policies for Marijuana Policy Project, said that while he hasn’t read the entire bill, it does look like it would create a medical marijuana program that “would benefit a lot of sick Floridans who otherwise suffer.” Capecchi explained that MPP does not consider Florida’s current law to be a “medical marijuana program” because it excludes too many patients from legally obtaining cannabis for medical use. “This would change all that,” Capecchi said.

To date, 23 states have legalized marijuana for medical purposes and 11 others, including Florida, have enacted the limited CBD-only laws. Still, the federal government bans the plant, classifying marijuana as a Schedule I substance with “no currently accepted medical use,” alongside heroin and LSD.


Child Abuse Charges for Mom who Gave Kids Cannabis for ADHD

Child Abuse Charges for Mom who Gave Kids Cannabis for ADHD

The side effects of the most commonly prescribed stimulant medications (like Adderall or Ritalin) for ADD (Attention Deficit Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) are truly frightening: higher blood pressure, loss of appetite, weight loss, stomach upset/pain, nausea/vomiting, dizziness, headache, diarrhea, dry mouth, fever and nervousness. Those are considered normal; severe side effects include numbness or pain in extremities, dangerously prolonged erections in male patients, uncontrollable teeth grinding, irregular heartbeat and seizures. That’s a very long list of serious side effects, and it would be enough to have any parent considering their options.

Amy Renee Cunningham is a 31-year-old mother of two boys who lives in Meswick, Michigan, and she allegedly decided to try to treat her sons with cannabis instead of the pharmaceutical drugs they were being prescribed. She allegedly gave her 12-year-old son access to smoked cannabis in lieu of his prescribed medications for ADHD. It has been reported that her 10-year-old was also using cannabis with her permission to deal with emotional issues. Both the children and the mother spoke with Child Protective Services about their use of cannabis as an alternative medicine, and the predictable fallout ensued.

Currently, Cunningham faces not only delivery/manufacture of marijuana charges but third-degree child abuse charges as well. While parents should not be making major medical decisions without proper guidance from a physician or other healthcare professional, it hardly seems reasonable to call her decision to pursue a medication with fewer dangerous side effects abuse. At worst, it was a misguided effort to help her sons.

While Michigan is a medical marijuana state and children are allowed to participate in the state’s medical marijuana program, neither of Cunningham’s sons had a doctor recommendation or a state-issued medical marijuana ID card. She has made statements that she is attempting to obtain a physician’s recommendation for her sons, but it is unlikely she will succeed. Michigan has a very specific list of qualifying medical conditions, and ADHD is not included on that list. Depending on the nature of the emotional issues her younger son suffers, it is possible he could qualify for a medical marijuana card if his issues are rooted in PTSD, which is a qualifying condition.

For the time being, however, her charges stand. Now, in addition to struggling with ADHD and emotional issues, her sons have to deal with the stress of having their mother prosecuted in a small community. Unless new information comes to light, or there is a major shift in Michigan’s policy toward medical marijuana, it is likely this family will have to struggle through a protracted trial process and the inevitable involvement of family court and mandatory counselling and educational services.

Source: Child Abuse Charges for Mom who Gave Kids Cannabis for ADHD


Pediatric Academy Now Says Medical Cannabis May Help Ill Children

Pediatric Academy Now Says Medical Cannabis May Help Ill Children

Marijuana use should be decriminalized and federal officials should reclassify cannabis as a less dangerous drug to spur vital medical research, the leading group of U.S. pediatricians recommended Monday.

In an update to its 2004 policy statement on pot, the American Academy of Pediatrics (AAP) also recognized marijuana may be a treatment option for kids “with life-limiting or severely debilitating conditions for whom current therapies are inadequate.”

That new stance is welcome news to some 200 families with ill children who recently moved to Colorado — where marijuana is legal for adults — in searches for last-ditch cures. Those remedies include the pot strain called Charlotte’s Web, which anecdotally has been shown to control seizures in some kids.

“We don’t want to marginalize families who feel like this is the only option for their child because of crisis,” said Dr. Sharon Levy, chair of AAP’s committee on substance abuse and assistant professor of pediatrics at Harvard Medical School. She was one of the statement’s co-authors.

Media accounts of medical-marijuana refugees in Colorado have given doctors “reason to suspect” that cannabinoids — the chemical compounds secreted by cannabis flowers — might have anticonvulsant properties, Levy said.

Charlotte’s Web, for example, is selectively bred to contain low levels of the cannabinoid THC, which causes people to feel high, but elevated levels of cannabidiol, or CBD, which does not have psychoactive effects. In one medical trial, CBD was shown to be possibly effective in treating people with Parkinson’s disease, though more study is needed, scientists have said.

“We understand why a desperate parent might say, ‘Look it’s going to take 10 years to do this research.’ We think that kind of compassionate use should be limited to children who are truly debilitated or at the end of life,” Levy said in an interview with NBC News. Asked to list those debilitating illnesses, Levy cited severe seizure disorders.

The AAP remains otherwise opposed to marijuana use among children and adolescents through the age of 21, and it continues to stand against the broader legalization of pot.

But the pediatricians’ group will now suggest that the federal government change marijuana from a Schedule I illegal drug (where it’s classified along side heroin) to a Schedule II controlled substance, Levy said. The U.S. Drug Enforcement Administration lists Adderall or Ritalin as examples of Schedule II drugs.

That change would facilitate a needed, new wave of cannabinoid research, the academy contends.

“There’s never been a study of cannabinoids in any form that has included children. With that in mind, the AAP cannot endorse use of cannabinoid medication with children,” Levy said. “We do note, though, there have been anecdotal cases that look promising. And that suggests there’s a need for study.

“We support reducing the barriers to do that.”

In addition, the academy said it now “strongly supports” the decriminalization of marijuana use — and encourages pediatricians “to advocate for laws that prevent harsh criminal penalties for possession or use of marijuana.”

The group’s revised policies will be published in the March issue of the journal Pediatrics.

In 18 states, the punishments for marijuana possession have been made far less punitive, though pot use remains illegal. While those shifts are not applicable to adolescents, they “are intended to address and reduce the long-term effects that felony charges can have on youth and young adults,” the academy noted.

Meanwhile, with medical-marijuana dispensaries operating legally in 23 states and the District of Columbia, the academy remains concerned that the shops are “very lightly regulated, and are run and staffed by people who don’t necessarily have a lot of medical training,” Levy said.

And the academy is aware of a slight increase in the number of U.S. kids who find and eat pot-infused candies and other treats sold at dispensaries.

During the first half of 2014 in Colorado, 14 children aged 3 to 7 were brought to emergency rooms to be treated for accidental ingestions of marijuana — compared to eight such cases during 2013 and an annual average of four cases from 2008 to 2012, reports the anti-legalization group Smart Approaches to Marijuana.

“A lot of that is quote-unquote medical marijuana that people are buying from medical marijuana shops in the form of cookies and candies, and kids are getting into that,” Levy said.

“We’ve even been seeing some lookalikes to popular products that are very attractive to kids — for example, instead of a Klondike Bar, there’s a Krondike Bar,” Levy said.

Dispensary employees do check the identifications of patrons to ensure they are 21 or older, and they routinely teach parents and other adults how to properly keep pot and cannabis-infused edibles out of the hands of children, said Michael Elliott, executive director of the Marijuana Industry Group, a trade association.

“Our industry doesn’t sell to those who shouldn’t have this product. Our industry is involved in numerous public education campaigns and we talk to our customers about responsible use and storage,” Elliott said.

“The black market dealer will sell to anyone. We don’t. While we can agree with the academy that marijuana may be harmful to children, (cannabis) prohibition has failed to keep our children safe,” Elliott added. “Alcohol and cigarettes are also harmful to children, but legal for adults to consume.”

Source: Pediatric Academy Now Says Medical Cannabis May Help Ill Children


Top Four Benefits of Cannabis for Glaucoma

Top Four Benefits of Cannabis for Glaucoma

The ability of cannabis to improve the symptoms of glaucoma has been demonstrated in various studies, but doubts still remain over its efficacy and consistency within patient populations. Despite this, many medical cannabis patients utilize cannabis for glaucoma, and report subjective improvements in various symptoms.

Reduces intraocular pressure

Increased intraocular pressure (ocular hypertension) is the risk factor in the majority of glaucoma cases, although it is absent in certain populations in almost 50% of individuals suffering from open-angle glaucoma (OAG)—the most common type, comprising around 90% of all cases. Intraocular pressure is determined by the production of aqueous humour in the eye coupled with the rate of drainage of the aqueous humour via the trabecular meshwork, a spongy tissue located at the base of the cornea. Consistently high intraocular pressure can cause progressive damage to the optic nerve and the retinal ganglion cells that contain light-sensitive photoreceptors. If damage is severe enough, total blindness can result.

Glaucoma is a common disease affecting the eyes, that increases in frequency with age (© 0olong)
Glaucoma is a common disease affecting the eyes, that increases in frequency with age (© 0olong)
During his decades-long tenure at the University of the West Indies, the respected pharmacologist Professor Manley West conducted landmark research into cannabis as a potential treatment for glaucoma alongside the noted ophthalmologist Dr. Albert Lockhart. As a result of their work, which began in 1964 and investigated traditional cannabis use in Jamaican communities, they developed cannabis-based eye-drops and gained approval to market their product in Jamaica under the name “Canasol”, in 1987. Professor West sadly died in 2012, and will be much missed by the medical cannabis community in Jamaica and beyond.

Canasol has been demonstrated to be effective in lowering intraocular pressure, and has also been shown to potentiate the effectiveness of other widely-used glaucoma drugs such as Timolol. Recently, a new and improved drug was developed by the same research team; this drug is known as Cantimol, and contains Canasol and Timolol, but has not yet been approval for market. Canasol contains no psychoactive cannabinoids and has also been widely prescribed by physicians in the USA and Canada—and has apparently been used by patients in the UK and Australia too, despite not having market approval or a legal precedent for use.

Miotic

A common phenomenon found in glaucoma patients is mydriasis, in which the pupil becomes dilated. In fact, it is thought that extreme mydriasis may actually cause the characteristic bulging-out of the iris in attacks of closed-angle glaucoma—in order for the pupil to dilate, muscle tissue in the iris (known as the dilator pupillae) must contract. When muscle tissue contracts, it bulges, and in extreme cases this bulging tissue can expand into the anterior chamber (the fluid-filled space between the iris and cornea) and press up against the cornea, totally preventing escape of aqueous humour via the anterior chamber and into the trabecular meshwork.

The opposite of mydriasis is miosis (not to be confused with the form of cell division known as meiosis). Miotic drugs are highly useful in glaucoma treatment, not only CAG, as constriction of the pupil allows increased drainage of aqueous humour into the trabecular meshwork. Cannabis has been shown to possess miotic properties on various occasions, including one notable case of apparent acute cannabis poisoning in a 20-month-old infant.

Analgesic

While the majority of glaucoma cases are painless, the rarer form of the disease (known as closed-angle glaucoma or CAG) is characterized by sharp, stabbing pains in the eyeball and rapid loss of vision, which may be permanent if not given medical attention. Closed angle glaucoma differs from the more common form in that it produces acute symptoms instead of chronic (and generally painless) symptoms. An attack of CAG is considered a medical emergency, and occurs due to a total blockage of the trabecular network (rather than a progressively reduced ability to drain aqueous humour, as with OAG) caused by a sudden bulging forward of the iris.

Although not specifically tested as an analgesic in glaucoma cases, cannabis’ wide-spectrum efficacy as an analgesic, mood-enhancer and muscle relaxant may provide subjective relief to individuals suffering from acute attacks of closed-angle glaucoma.

Anti-inflammatory

On the basis of recent research, some medical professionals are beginning to suspect that persistent, low-level inflammation in the trabecular meshwork may have an important role to play in the progressive, chronic form of glaucoma, OAG. As well as this, a further type of glaucoma that is often found in patients suffering from uveitis (inflammation of the uvea, the area of the eye that contains the iris and the ciliary body) is known as inflammatory glaucoma as it has been proven that inflammation of the trabecular meshwork is to blame. In most respects, inflammatory glaucoma resembles OAG, but is characterized as occurring as a secondary symptom of uveitis.

Cannabis has been proven time and time again to be a useful and effective anti-inflammatory for a range of different conditions, although no formal studies have been conducted on the potential of cannabis to reduced glaucoma-related inflammation. As understanding of the role inflammation has to play in the progression of the disease increases, it may well prove to be the case that cannabis also provides relief to glaucoma patients due to its anti-inflammatory properties.

Antinauseant/antiemetic

Attacks of closed-angle glaucoma are often accompanied by secondary symptoms of nausea and vomiting, which is believed to arise as a result of a phenomenon known as the oculoemetic reflex. Various past studies have shown an association with ophthalmic surgery and post-operative vomiting (particularly squint surgery, which causes vomiting in 41% of patients), which gave rise to the possibility of the oculoemetic reflex existing.

It is believed that noxious (painful or unpleasant) stimulation of the orbital nerves that surround the eye sends signals to the area postrema of the medulla oblongata, the section of the brain that is often simply known as the vomiting centre. The brain then sends signals to the gastrointestinal tract via the vagus nerve (a fundamental part of the parasympathetic nervous system, which controls cardiac and gastrointestinal function), which in turn causes the vomiting reflex by stimulating retroperistalsis (backward/upward movement of GI tract contents).

It is not known what precise role the endocannabinoid system has to play in regulation of vomiting, but it has been shown that cannabinoid receptor agonists such as THC appear to directly suppress vomiting and nausea by agonizing the CB₁-receptor –while antagonists of the CB receptors such as CBD are neutral, and inverse agonists actually cause nausea.

Source: Top Four Benefits of Cannabis for Glaucoma


Cannabis eases chronic pain better than commonly prescribed opioids

Cannabis eases chronic pain better than commonly prescribed opioids

Cannabis can ease chronic pain more effectively than conventional medicines, according to a new study likely to flame the debate on the medical use of marijuana.

Researchers from the Australian National Drug and Alcohol centre found that patients with chronic pain who used the drug said it eased their symptoms better opioid medications, which are highly addictive and can cause accidental overdoses.

The study analysed 1,500 patients, aged in their late 40s and early 50s, who suffered from conditions including back pain, migraines and arthritis, and were being prescribed with heavy-duty opioid medications, such as morphine and oxycodone.

Professor Louisa Degenhardt, from the National Drug and Alcohol Centre and the University of Melbourne led the study. Her team discovered that nearly 13 per cent of the patients had used the illegal drug in the past year on top of their prescribed medication.

In comparison, only 4.7 per cent of the rest of the population used cannabis, she wrote in the journal ‘Drug and Alcohol Dependence’.

“One in three said they found it very effective to relieve their pain, that’s a score of ten out of ten,” she told the Sydney Morning Herald. “Now these are all subjective scores, but it means there is definitely a group of people who think that taking it was very beneficial.”

Degenhart added that the study raised vital questions over whether cannabis should be more seriously explored as source of pain relief, as well as the negative effects of drugs, such as patient dependence.

Dr Nicholas Lintzeris, the co-author of the study and an associate professor of addiction medicine at the University of Sydney, said a huge number of Australians were seeking help for addiction to pain medications, as doctors are left with little choice but to prescribe strong painkillers. This was caused by a lack of access to treatments such as massage, he said.

The findings come after a father who was arrested for allegedly giving his two-year-old daughter cannabis oil sparked a debate on the drug’s use in medicine this month.

Source: Cannabis eases chronic pain better than commonly prescribed opioids


Cannabis may slow or stop the progression of Alzheimer's Disease.

Cannabis may slow or stop the progression of Alzheimer’s Disease.

Medical marijuana advocates in Maine are trying to spread the word about a recent study indicating the drug may slow or stop the progression of Alzheimer’s Disease.

The Gelassen family of Portland says it works.

Allen Gelassen is a pretty happy guy despite living with Alzheimer’s.

“I always have a problem (remembering) day-to-day,”said Gelassen, “But distance, some of it I can, some of it I can’t.”

The diagnosis came a few months ago, after the stroke that left him in a wheelchair. And with it, prescription painkillers; something that impacted his kids’ lives too.

“Groggy, depressed,” said his son, Benjamin Gelassen, “Which put that energy onto me.”

But recently, Gelassen ditched the prescriptions and decided to stick solely to medical marijuana.

Ever since, Benjamin Gelassen said his dad seems to have stopped deteriorating.

“He’s able to hold up in a conversation and remember things stated five minutes earlier or a week ago,” said Benjamin Gelassen.

In a preclinical study, researchers at the University of South Florida found that extremely low levels of THC, a chemical in marijuana, have positive effects on the protein that builds up in the brain and leads to Alzheimer’s.

According to the National Institute on Drug Abuse, marijuana can be addictive and health concerns include impaired judgement, slow reaction time and mood effects. But authors of the study said they’re talking about such a small amount of THC, they believe the benefits outweigh the risk. They also acknowledge it isn’t for everyone.

“This is an option for them,” said Becky Dekeuster, co-founder of The Wellness Connection of Maine, which operates half of Maine’s dispensaries.

Dekeuster said there are currently no clients in the Alzheimer’s category, but she’s hoping to change that.

“I wonder if that’s because the qualifying condition is at a later stage, at a time when the family is not really looking for new things,” said Dekeuster. “They’re trying to manage the situation.”

Benjamin Gelassen wants to see more families benefit.

“(My dad is) alot happier and it makes me happy,” he said.